Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)

Inclusion Criteria: * Age ≥ 18 years, male or female * Signed written informed consent * Patients with histologically confirmed diagnosis of colorectal cancer with hepatic metastases who are candidates for systemic treatment. * Confirmation of metastatic liver disease within one month prior to inclusion in one of the following radiological procedures: * Contrast-enhanced spiral computed tomography showing at least one liver nodule ≥ 20 mm in longest diameter according to RECIST 1.1 criteria * MR imaging of the liver with liver lesions suspicious for metastases * PET computed tomography (PET/CT) with liver lesions suspicious for metastases * Patient is eligible and designated for treatment with standard-of-care first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy. * ECOG performance status ≤ 2 (see appendix) Exclusion Criteria: * Inability or unwillingness to comply with the participation requirements * History of untreated hyperthyreosis * History of intolerance of or allergy to iodine contrast media according to CTCAE V4.03 * Calculated creatinine clearance \< 45 ml/min * For fertile women: positive urine pregnancy test or lactation. * Known or suspected non-compliance, drug or alcohol abuse * Life expectancy of less than 3 months * Participation in another interventional trial with an investigational medicinal product (IMP) and within 30 days prior to screening